| Benefits of rivastigmine on attention in dementia associated with Parkinson disease PD K.A. Wesnes, MD I. McKeith, MS C. Edgar, MD M. Emre, ... Neurology 65, 1654-1656, 2005 | 195 | 2005 |
| Cocaine users differ from normals on cognitive tasks which show poorer performance during drug abstinence EF Pace-Schott, PT Morgan, RT Malison, CL Hart, C Edgar, M Walker, ... The American journal of drug and alcohol abuse 34 (1), 109-121, 2008 | 115 | 2008 |
| Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg KA Wesnes, C Edgar, RN Tretter, J Bolodeoku Expert opinion on drug safety 8 (6), 615-626, 2009 | 108 | 2009 |
| The cognitive and psychomotor effects of remacemide and carbamazepine in newly diagnosed epilepsy KA Wesnes, C Edgar, ADP Dean, SJ Wroe Epilepsy & behavior 14 (3), 522-528, 2009 | 85 | 2009 |
| Performance on a pattern separation task by Alzheimer’s patients shows possible links between disrupted dentate gyrus activity and apolipoprotein E∈ 4 status and cerebrospinal … KA Wesnes, P Annas, H Basun, C Edgar, K Blennow Alzheimer's research & therapy 6, 1-8, 2014 | 74 | 2014 |
| Outcomes assessment in clinical trials of Alzheimer’s disease and its precursors: readying for short-term and long-term clinical trial needs H Posner, R Curiel, C Edgar, S Hendrix, E Liu, DA Loewenstein, ... Innovations in clinical neuroscience 14 (1-2), 22, 2017 | 61 | 2017 |
| Cognitive performance in relapsing remitting multiple sclerosis: a longitudinal study in daily practice using a brief computerized cognitive battery C Edgar, PJ Jongen, E Sanders, C Sindic, S Goffette, M Dupuis, ... BMC neurology 11, 1-11, 2011 | 57 | 2011 |
| Nabilone produces marked impairments to cognitive function and changes in subjective state in healthy volunteers KA Wesnes, P Annas, CJ Edgar, C Deeprose, R Karlsten, A Philipp, ... Journal of Psychopharmacology 24 (11), 1659-1669, 2010 | 51 | 2010 |
| Relationship between working hours and power of attention, memory, fatigue, depression and self-efficacy one year after diagnosis of clinically isolated syndrome and relapsing … PJ Jongen, K Wesnes, B Van Geel, P Pop, E Sanders, H Schrijver, ... PloS one 9 (5), e96444, 2014 | 46 | 2014 |
| Cognitive performance by humans during a smoked cocaine binge-abstinence cycle EF Pace-Schott, R Stickgold, A Muzur, PE Wigren, AS Ward, CL Hart, ... The American journal of drug and alcohol abuse 31 (4), 571-591, 2005 | 46 | 2005 |
| Defining therapeutic benefit for people with schizophrenia: focus on negative symptoms NR Schooler, RW Buchanan, T Laughren, S Leucht, HA Nasrallah, ... Schizophrenia Research 162 (1-3), 169-174, 2015 | 43 | 2015 |
| Effects of nicotine withdrawal on cognition in a clinical trial setting KA Wesnes, CJ Edgar, I Kezic, HM Salih, P de Boer Psychopharmacology 229, 133-140, 2013 | 42 | 2013 |
| Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent … CJ Edgar, T Blaettler, D Bugarski-Kirola, S Le Scouiller, GM Garibaldi, ... Psychiatry research 218 (1-2), 219-224, 2014 | 40 | 2014 |
| Clinically relevant changes for cognitive outcomes in preclinical and prodromal cognitive stages: Implications for clinical Alzheimer trials E Borland, C Edgar, E Stomrud, N Cullen, O Hansson, S Palmqvist Neurology 99 (11), e1142-e1153, 2022 | 32 | 2022 |
| Psychometric properties of the Clinical Dementia Rating—Sum of Boxes and other cognitive and functional outcomes in a prodromal Alzheimer’s disease population F McDougall, C Edgar, M Mertes, P Delmar, P Fontoura, D Abi-Saab, ... The Journal of Prevention of Alzheimer's Disease 8, 151-160, 2021 | 32 | 2021 |
| Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials JB Langbaum, J Zissimopoulos, R Au, N Bose, CJ Edgar, E Ehrenberg, ... Alzheimer's & Dementia 19 (2), 696-707, 2023 | 31 | 2023 |
| The 2018 revised FDA guidance for early Alzheimer’s disease: establishing the meaningfulness of treatment effects CJ Edgar, G Vradenburg, J Hassenstab The journal of prevention of Alzheimer's disease 6, 223-227, 2019 | 28 | 2019 |
| Dapoxetine has no pharmacokinetic or cognitive interactions with ethanol in healthy male volunteers NB Modi, M Dresser, D Desai, C Edgar, K Wesnes The Journal of Clinical Pharmacology 47 (3), 315-322, 2007 | 27 | 2007 |
| Building clinically relevant outcomes across the Alzheimer's disease spectrum DM Rentz, AM Wessels, AV Annapragada, AK Berger, CJ Edgar, M Gold, ... Alzheimer's & Dementia: Translational Research & Clinical Interventions 7 (1 …, 2021 | 26 | 2021 |
| DT‐01‐03: Efficacy and safety of gantenerumab in prodromal Alzheimer's disease: Results from scarlet road—a global, multicenter trial R Lasser, S Ostrowitzki, P Scheltens, M Boada, B Dubois, E Dorflinger, ... Alzheimer's & Dementia 11 (7S_Part_7), P331-P332, 2015 | 24 | 2015 |
Professor Keith Andrew WesnesHead Honcho, Wesnes Cognition Ltd, RG8 9RD, UK在 wesnes.com 的电子邮件经过验证
